CA2537955A1 - Diagnostic marker for ovarian cancer - Google Patents

Diagnostic marker for ovarian cancer Download PDF

Info

Publication number
CA2537955A1
CA2537955A1 CA002537955A CA2537955A CA2537955A1 CA 2537955 A1 CA2537955 A1 CA 2537955A1 CA 002537955 A CA002537955 A CA 002537955A CA 2537955 A CA2537955 A CA 2537955A CA 2537955 A1 CA2537955 A1 CA 2537955A1
Authority
CA
Canada
Prior art keywords
haptoglobin
precursor
ovarian cancer
antibody
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002537955A
Other languages
English (en)
French (fr)
Inventor
Nuzhat Ahmed
Gregory Edward Rice
Michael Anthony Quinn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Royal Womens Hospital
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2003904844A external-priority patent/AU2003904844A0/en
Application filed by Individual filed Critical Individual
Publication of CA2537955A1 publication Critical patent/CA2537955A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002537955A 2003-09-05 2004-09-06 Diagnostic marker for ovarian cancer Abandoned CA2537955A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003904844 2003-09-05
AU2003904844A AU2003904844A0 (en) 2003-09-05 Diagnostic marker
PCT/AU2004/001205 WO2005024054A1 (en) 2003-09-05 2004-09-06 Diagnostic marker for ovarian cancer

Publications (1)

Publication Number Publication Date
CA2537955A1 true CA2537955A1 (en) 2005-03-17

Family

ID=34230078

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002537955A Abandoned CA2537955A1 (en) 2003-09-05 2004-09-06 Diagnostic marker for ovarian cancer

Country Status (6)

Country Link
US (1) US20070053896A1 (enExample)
EP (1) EP1668149A4 (enExample)
JP (1) JP2007504463A (enExample)
CN (1) CN1871362A (enExample)
CA (1) CA2537955A1 (enExample)
WO (1) WO2005024054A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114324557A (zh) * 2021-12-03 2022-04-12 融智生物科技（青岛）有限公司 一种基于MALDI-TOF MS的ζ-珠蛋白的检测方法

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
CN101243319B (zh) 2005-06-22 2016-01-06 约翰·霍普金斯大学 卵巢癌的生物标记：ctap3-相关蛋白质
JP5237817B2 (ja) * 2005-10-21 2013-07-17 ジーンニュース インコーポレーティッド バイオマーカー産物レベルを疾患に相関させるための方法および装置
EP2363205A3 (en) 2006-01-11 2014-06-04 Raindance Technologies, Inc. Microfluidic Devices And Methods Of Use In The Formation And Control Of Nanoreactors
EP1987360B1 (en) * 2006-01-27 2012-03-07 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP2530168B1 (en) 2006-05-11 2015-09-16 Raindance Technologies, Inc. Microfluidic Devices
EP2077912B1 (en) 2006-08-07 2019-03-27 The President and Fellows of Harvard College Fluorocarbon emulsion stabilizing surfactants
SG140505A1 (en) * 2006-09-05 2008-03-28 Univ Singapore Diagnostic biomolecule(s)
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
WO2010009365A1 (en) 2008-07-18 2010-01-21 Raindance Technologies, Inc. Droplet libraries
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
JP5422785B2 (ja) * 2008-09-12 2014-02-19 国立大学法人名古屋大学 質量分析法を利用した複数癌腫の血液検出のための方法および生物マーカー
US8528589B2 (en) 2009-03-23 2013-09-10 Raindance Technologies, Inc. Manipulation of microfluidic droplets
GB0917044D0 (en) * 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
US10520500B2 (en) 2009-10-09 2019-12-31 Abdeslam El Harrak Labelled silica-based nanomaterial with enhanced properties and uses thereof
EP2517025B1 (en) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Methods for reducing the exchange of molecules between droplets
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
JP5934657B2 (ja) 2010-02-12 2016-06-15 レインダンス テクノロジーズ， インコーポレイテッド デジタル検体分析
WO2011143292A1 (en) * 2010-05-11 2011-11-17 Ohio University Biomarkers for detecting erythropoietin use in human subjects
KR101313184B1 (ko) * 2010-06-24 2013-09-30 한국표준과학연구원 질병 지표 검출 키트 및 질병 지표 검출 방법
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
EP3859011A1 (en) 2011-02-11 2021-08-04 Bio-Rad Laboratories, Inc. Methods for forming mixed droplets
EP2675819B1 (en) 2011-02-18 2020-04-08 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
DE202012013668U1 (de) 2011-06-02 2019-04-18 Raindance Technologies, Inc. Enzymquantifizierung
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
WO2012174569A2 (en) * 2011-06-17 2012-12-20 The Board Of Trustees Of The University Of Arkansas New markers for early diagnosis of ovarian cancer, monitoring during therapy, and new therapy options during and after chematherapy
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
WO2013120089A1 (en) 2012-02-10 2013-08-15 Raindance Technologies, Inc. Molecular diagnostic screening assay
EP2844768B1 (en) 2012-04-30 2019-03-13 Raindance Technologies, Inc. Digital analyte analysis
EP2986762B1 (en) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digital analyte analysis
CN104225619B (zh) * 2013-06-09 2018-04-17 上海吉凯基因化学技术有限公司 人ilk基因治疗肿瘤的用途及其相关药物
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
KR101582416B1 (ko) * 2014-06-30 2016-01-06 가톨릭대학교 산학협력단 프로합토글로빈을 이용한 간암 진단방법
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
AU2017244763A1 (en) * 2016-03-29 2018-10-18 Kyowa Kirin Co., Ltd. Autoimmune disease therapeutic agent containing, as active ingredient, antibody that binds to haptoglobin in blood to form polyvalent immune complex
CN106520924A (zh) * 2016-10-14 2017-03-22 浙江大学 一种用于检测卵巢癌的引物组及检测方法
CN106544421B (zh) * 2016-10-21 2020-05-08 武汉科技大学 Spag6基因作为卵巢肿瘤诊断和治疗标志物的用途
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946774A (en) * 1987-11-09 1990-08-07 Trustees Of Boston University Process for detecting cancer and for monitoring the effectiveness of cancer therapy
KR0174528B1 (ko) * 1989-01-17 1999-05-15 마이클 이. 존스 암과 관련된 헵토글로빈
GB9805477D0 (en) * 1998-03-13 1998-05-13 Oxford Glycosciences Limited Methods and compositions for diagnosis of rheumatoid arthritis
US7112408B2 (en) * 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
AU2002335963A1 (en) * 2001-11-23 2003-06-10 Syn.X Pharma, Inc. Protein biopolymer markers predictive of alzheimers disease
AU2003235749A1 (en) * 2002-01-07 2003-07-24 John Hopkins University Biomarkers for detecting ovarian cancer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114324557A (zh) * 2021-12-03 2022-04-12 融智生物科技（青岛）有限公司 一种基于MALDI-TOF MS的ζ-珠蛋白的检测方法
CN114324557B (zh) * 2021-12-03 2024-05-10 融智生物科技（青岛）有限公司 一种基于MALDI-TOF MS的ζ-珠蛋白的检测方法

Also Published As

Publication number Publication date
EP1668149A4 (en) 2007-01-03
JP2007504463A (ja) 2007-03-01
WO2005024054A1 (en) 2005-03-17
CN1871362A (zh) 2006-11-29
US20070053896A1 (en) 2007-03-08
EP1668149A1 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
US20070053896A1 (en) Diagnostic marker for ovarian cancer
Ahmed et al. Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer
Ye et al. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine
US20090209431A1 (en) Non-Invasive in Vitro Method to Detect Transitional Cell Carcinoma of the Bladder
US20190285637A1 (en) Biomarkers for gastric cancer and uses thereof
EP2375254A1 (en) Free NGAL as a biomarker for cancer
Yang et al. Immuno-proteomic discovery of tumor tissue autoantigens identifies olfactomedin 4, CD11b, and integrin alpha-2 as markers of colorectal cancer with liver metastases
WO2011035433A1 (en) Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
Yamashita et al. Serum level of HE4 is closely associated with pulmonary adenocarcinoma progression
US20140274794A1 (en) Methods and Compositions for Diagnosis of Ovarian Cancer
CA2453580A1 (en) Detection of ovarian cancer based upon alpha-haptoglobin levels
WO2009039023A2 (en) Detection of saliva proteins modulated secondary to ductal carcinoma in situ of the breast
US20100216654A1 (en) Biomarkers of prostate cancer and uses thereof
WO2010015659A1 (en) Cancer markers and methods for their detection
US8642347B2 (en) Urinary CA125 peptides as biomarkers of ovarian cancer
EP3092495B1 (en) Srm assay for pd-l1
Chahed et al. Detection of protein alterations in male breast cancer using two dimensional gel electrophoresis and mass spectrometry: the involvement of several pathways in tumorigenesis
Gibson et al. Stratification and monitoring of juvenile idiopathic arthritis patients by synovial proteome analysis
KR102402428B1 (ko) 난소암 진단용 다중 바이오 마커 및 이의 용도
Zhang et al. Tumor associated glycoprotein-72 is a novel marker for poor survival in hepatocellular carcinoma
Zhang et al. Comparative analysis of the human urinary proteome by 1D SDS-PAGE and chip-HPLC-MS/MS identification of the AACT putative urinary biomarker
Peng et al. A rat‐to‐human search for proteomic alterations reveals transgelin as a biomarker relevant to colorectal carcinogenesis and liver metastasis
CN114791492B (zh) Cst1联合gpx4作为胃癌转移标志物或预后标志物的应用
WO2009034562A2 (en) A method of assessing lung squamous cell carcinoma status in an individual
AU2004270759A1 (en) Diagnostic marker for ovarian cancer

Legal Events

Date Code Title Description
FZDE Discontinued